title: IGF-I treatment facilitates transition from parenteral to enteral nutrition in rats with short bowel syndrome.
abstract: The goal of growth factor treatment in patients with short bowel syndrome (SBS) is to facilitate transition from parenteral to enteral feedings. Ideal use of growth factors would be acute treatment that produces sustained effects. We investigated the ability of acute insulin-like growth factor I (IGF-I) treatment to facilitate weaning from total parenteral nutrition (TPN) to enteral feeding in a rat model of SBS. After a 60% jejunoileal resection + cecectomy, rats treated with IGF-I or vehicle were maintained exclusively with TPN for 4 days and transitioned to oral feeding. TPN and IGF-I were stopped 7 days after resection, and rats were maintained with oral feeding for 10 more days. In IGF-I-treated rats, serum concentration of IGF-I and final body weight were significantly greater because of a proportionate increase in carcass lean body mass than in vehicle-treated rats. Acute IGF-I treatment induced sustained jejunal hyperplasia on the basis of significantly greater concentrations of jejunal mucosal protein and DNA without a change in histology or sucrase activity. These results demonstrate that acute IGF-I facilitates weaning from parenteral to enteral nutrition in association with maintenance of a greater body weight and serum IGF-I concentration in rats with SBS.
authors.affiliation: Department of Nutritional Sciences, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA.
authors.forename: Melanie B
authors.initials: MB
authors.lastname: Gillingham
authors.forename: Elizabeth M
authors.initials: EM
authors.lastname: Dahly
authors.forename: Sangita G
authors.initials: SG
authors.lastname: Murali
authors.forename: Denise M
authors.initials: DM
authors.lastname: Ney
mesh_terms: D000818:Animals; D001823:Body Composition / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D003106:Colon / Q000187:drug effects / Q000378:metabolism; D004195:Disease Models, Animal; D004734:Energy Metabolism / Q000187:drug effects; D004750:Enteral Nutrition; D007334:Insulin-Like Growth Factor I / Q000032:analysis / Q000235:genetics / Q000494:pharmacology*; D007413:Intestinal Mucosa / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism; D007583:Jejunum / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism; D008297:Male; D009929:Organ Size / Q000187:drug effects; D010288:Parenteral Nutrition; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D012778:Short Bowel Syndrome / Q000178:diet therapy* / Q000188:drug therapy* / Q000235:genetics; D013393:Sucrase / Q000378:metabolism
chemical_list: D012333:RNA, Messenger; D007334:Insulin-Like Growth Factor I; D013393:Sucrase